Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 7/20 | 0.41 |
| ▸ | FLT3 | P36888 | 5/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.38 |
| ▸ | MERTK | Q12866 | 3/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.34 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.34 |
| ▸ | AXL | P30530 | 1/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.33 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6521319 | 1.00 | SYK (0.41) | SYKFLT3CHEK1MERTKTYRO3 | |
| SCHEMBL1159235 | 1.00 | SYK (0.41) | SYKFLT3CHEK1MERTKTYRO3 | |
| SCHEMBL6526514 | 0.87 | SYK (0.38) | SYKFLT3CHEK1GRM2 | |
| SCHEMBL6520001 | 0.85 | SYK (0.58) | SYKFLT3CHEK1GRM2 | |
| SCHEMBL12797876 | 0.85 | SYK (0.58) | SYKFLT3CHEK1GRM2 | |
| SCHEMBL1158903 | 0.85 | SYK (0.58) | SYKFLT3CHEK1GRM2 | |
| SCHEMBL6524136 | 0.85 | SYK (0.58) | SYKFLT3CHEK1GRM2 | |
| SCHEMBL6520661 | 0.85 | SYK (0.36) | SYKFLT3CHEK1MKNK1MKNK2 | |
| SCHEMBL1158978 | 0.85 | SYK (0.36) | SYKFLT3CHEK1MKNK1MKNK2 | |
| SCHEMBL1158851 | 0.84 | SYK (0.56) | SYKFLT3CHEK1MERTKTYRO3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | claimed |
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| WO-2011014515-A1 | 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS | IRM LLC (BM) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053897-A1 | COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS | SYK, BTK, LYN | SYK 1/4885FLT3 40/4885CHEK1 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.